Antiprogesterone RU 486—a Drug for Non-Surgical Abortion

References

• Diczfalusy E. Contraception futurology. Future aspects in contraception, B Runnebaum, T Rabe, L Kiesel. MTP Press, Lancaster 1985; 361–8
   Google Scholar
• Ritamies M. Abortit meilläjamuualla. Publications of the Population Research Institute D 16. Vammalan Kirjapaino, Vammala 1986; 18, (in Finnish)
   Google Scholar
• Csapo A, Pulkklnen M, Ruttner B, Sauvage J, Wiest W. The significance of the human corpus luteum in pregnancy maintenance. Am J Obstet Gynecol 1972; 112: 1061–7
   PubMed Web of Science ®Google Scholar
• Philibert D, Deraedt R, Teutsch G. RU 38486—A potent antiglucocorticoid in vivo. Eighth International Congress of Pharmacology, Tokyo, 1981, Abstract No. 1463
   Google Scholar
• Philibert D, Deraedt R, Teutsch G, Toumemine C, Sakiz E. RU 486: A new lead for steroidal anti‐hormones. Presented at the 64th Annual Meeting of the Endocrine Society, San Francisco, June, 16–181982, Abstract No. 688
   Google Scholar
• Population Crisis Committee: RU‐486: A new birth control option. 1989, no 3
   Google Scholar
• Allen W, Comer G. Physiology of corpus luteum VII. Maintenance of pregnancy in rabbit after very early castration, by corpus luteum extracts. Proc Soc Exp Biol & Med. 1930; 27: 403–5
   Google Scholar
• Butenandt A, Westphal U. Isolation of progesterone—forty years ago. Am J Obstet Gynecol 1974; 120: 137–41
   PubMed Web of Science ®Google Scholar
• Csapo A, Dray F, Erdos T. The biological effects of injected antibodies to estradiol‐17β and to the progesterone in pregnant rats. Endocrinology 1975; 97: 603–14
   PubMed Web of Science ®Google Scholar
• Csapo A, Resch B. Prevention of implantation by antiprogesterone. J Steroid Biochem 1979; 11: 963–9
   PubMedGoogle Scholar
• Bygdeman M, Christensen N, Green K, Zheng S, Lundström V. Termination of early pregnancy; future development. Acta Obstet Gynecol Scand 1983, Suppl 113: 125–9
   PubMedGoogle Scholar
• Birgerson L, Ölund A, Odlind V, Somell C. Termination of early human pregnancy with Epostane. Contraception 1987; 35: 111–20
   PubMed Web of Science ®Google Scholar
• Isola J. Immunoelectron microscopic localization of chick progesterone receptor. Thesis, University of Tampere, TampereFinland 1987
   Google Scholar
• Teutsch G. Analogues of RU 486 for the mapping of the progestin receptor: synthetic and structural aspects. The antiprogestin steroid RU 486 and human fertility control, E E Baulieu, S Segal. Plenum Press, New York 1985; 27–47
   Google Scholar
• Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu E E. Effet d'un stéroide anti‐progestérone chez la femme. Interruption du cycle menstruel et de la grossesse au début. C R Hebd Acad Seanc Sci Paris 1982; 294: 933–8
   Google Scholar
• Gravanis A, Schalson G, George M, de Brux J, Satyaswaroop P, Baulieu E E, Robel P. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 1985; 60: 156–63
   PubMed Web of Science ®Google Scholar
• Helkinheimo O, Kontula K, Croxatto H, Spitz I, Luukkalnen T, Lähteenmäkl P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 1987; 26: 279–84
   PubMedGoogle Scholar
• Rauch M, Loosfelt H, Philibert D, Milgrom E. Mechanism of action of an antiprogesterone, RU 486, in the rabbit endometrium. Eur J Biochem 1985; 148: 213–8
   PubMedGoogle Scholar
• Geler A, Bella R, Beery R, Halmsohn M, Lunenfeld B. Differences in the association of the progesterone receptor ligated by antiprogestin RU 38386 or progestin ORG 2058 to chromatin components. Biochem Biophys Acta 1987; 931: 78–86
   PubMedGoogle Scholar
• Moguilewsky M, Philibert D. RU 38486: Potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J Steroid Biochem 1984; 20: 271–6
   PubMedGoogle Scholar
• Rajpert E, Lemalgre F, El lard P, et al. Glucocorticoid receptors bound to the antagonist RU 486 are not downregulated despite their capacity to interact in vitro with defined gene regions. J Steroid Biochem 1987; 26: 513–20
   PubMedGoogle Scholar
• Schaison G, George M, Lestrat N, Reinberg A, Baulieu E E. Effects of the anti progesterone steroid RU 486 during midluteal phase in normal women. J Clin Endocrinol Metab 1985; 61: 484–9
   PubMed Web of Science ®Google Scholar
• Garzo V, Liu J, Ulmann A, Baulieu E E, Yen S. Effects of an antiprogesterone (RU 486) on the hypothalamic‐hypophyseal‐ovarian‐endometrial axis during the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 1988; 66: 508–17
   PubMed Web of Science ®Google Scholar
• Wolf J, Danforth D, Ulmann A, Baulieu E E, Hodgen G. Contraceptive potential of RU 486 by ovulation inhibition: II suppression of pituitary gonadotropin secretion In vitro. Contraception 1989; 40: 185–93
   PubMed Web of Science ®Google Scholar
• Soules M, Stelner R, Clifton D, Cohen N, Aksel S, Bremner W. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 1984; 58: 378–83
   PubMed Web of Science ®Google Scholar
• Liu J, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen S. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. J Clin Endocrinol Metab 1987; 65: 1135–40
   PubMed Web of Science ®Google Scholar
• Shoupe D, Mishell D, Jr, Page M, Madkour H, Spitz I, Lobo R. Effects of the antiprogesterone RU 486 in normal women, II. Administration in the late follicular phase. Am J Obstet Gynecol 1987; 157: 1421–6
   PubMed Web of Science ®Google Scholar
• Nieman L, Choate T, Chrousos G, et al. The progesterone antagonist RU 486, A potential new contraceptive agent. N Engl J Med 1987; 316: 187–91
   PubMed Web of Science ®Google Scholar
• Shoupe D, Mishell D, Jr, Lähteenmäki P, et al. Effects of the antiprogesterone RU 486 in normal women, I. Single‐dose administration in the midluteal phase. Am J Obstet Gynecol 1987; 157: 1415–20
   PubMed Web of Science ®Google Scholar
• Luukkalnen T, Heikinheimo O, Haukkamaa M, Lähteenmäkl P. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril 1988; 49: 961–3
   PubMed Web of Science ®Google Scholar
• Schreiber J, Nakamura K, Erickson G. Progestins inhibit FSH‐stimulated steroidogenesis in cultured rat granulosa cells. Mol Cell Endocrinol 1980; 19: 165–73
   PubMed Web of Science ®Google Scholar
• Chillik C, Hsiu J, Acosta A, van Uem J, Hodgen G. RU 486‐induced menses in cynomolgus monkeys: uniformity of endometrial sloughing. Fertil Steril 1986; 45: 708–12
   PubMed Web of Science ®Google Scholar
• Csapo A, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy luteectomy evidence. Obstet Gynecol Surv 1978; 33: 69–81
   PubMedGoogle Scholar
• Kelly W, Healy D, Cameron M, Cameron I, Baird D. The stimulation of prostaglandin production by two antiprogesterone steroids in human endometrial cells. J Clin Endocrinol Metab 1986; 62: 1116–23
   PubMed Web of Science ®Google Scholar
• Smith S, Kelly R. The effect of the antiprogestins RU 486 and ZK 98734 on the synthesis and metabolism of prostaglandins F2α and E2 in separated cells from early human decidua. J Clin Endocrinol Metab 1987; 65: 527–34
   PubMed Web of Science ®Google Scholar
• Swahn M, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynecol 1988; 95: 126–34
   PubMedGoogle Scholar
• Blschof P, Sizonenko M, Herrmann W. Trophoblastic and decidual responses to RU 486: effects on human chorionic gonadotrophin, human placental lactogen, prolactin and pregnancy‐associated plasma protein‐A production in vitro. Hum Reprod 1986; 1: 3–6
   PubMed Web of Science ®Google Scholar
• Das C, Catt K. Antifertility actions of the progesterone antagonist RU 486 include direct inhibition of placental hormone secretion. Lancet 1987; ii: 599–601
   Google Scholar
• Olajide F, Howell R, Wass J, et al. Circulating levels of placental protein 12 and chorionic gonadotrophin following RU 38486 and gemeprost for termination of first trimester pregnancy. Hum Reprod 1989; 4: 337–40
   PubMed Web of Science ®Google Scholar
• Bertagna X, Bertagna C, Luton J ‐P, Husson J ‐M, Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984; 59: 25–8
   PubMed Web of Science ®Google Scholar
• Gaillard R, Riondel A, Müller A, Herrmann W, Baulieu E E. RU 486: A steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary‐adrenal system at a specific time of day. Proc Natl Acad Sci USA 1984; 81: 3879–82
   PubMed Web of Science ®Google Scholar
• Healy D, Chrousos G, Schulte H, Gold P, Hodgen G. Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the antiglucocor‐ticoid steroid RU 486: dose response relationships. J Clin Endocrinol 1985; 60: 1–4
   PubMed Web of Science ®Google Scholar
• Wade C, Spitz I, Lähteenmäki P, Heikinheimo O, Krieger D, Bardin W. Effects of the antiglucocorticoid RU 486 on adrenal function in dogs. J Clin Endocrinol Metab 1988; 66: 473–9
   PubMed Web of Science ®Google Scholar
• Laue L, Chrousos G, Loriaux D, et al. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man. J Clin Endocrinol Metab 1988; 66: 290–3
   PubMed Web of Science ®Google Scholar
• Laue L, Gallucci W, Loriaux D, Edelsman R, Chrousos G. The antiglucocorticoid and antiprogestin steroid RU 486: its glucocorticoid agonist effect is inadequate to prevent adrenal insufficiency in primates. J Clin Endocrinol Metab 1988; 67: 602–6
   PubMed Web of Science ®Google Scholar
• Bardon S, Vignon F, Chalbos D, Rochefort H. RU 486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab 1985; 60: 692–7
   PubMed Web of Science ®Google Scholar
• Horwitz K. The antiprogestin RU 38486: receptor‐mediated progestin versus antiprogestin actions screened in estrogen‐insensitive T47Dco human breast cancer cells. Endocrinology 1985; 116: 2236–45
   PubMed Web of Science ®Google Scholar
• Gill P, Vignon F, Bardon S, Derocq D, Rochefort H. Difference between R5020 and the antiprogestin RU 486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res Treat 1987; 10: 37–45
   PubMed Web of Science ®Google Scholar
• Terakawa N, Shimizu I, Tanizawa O, Matsumoto K. RU 486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins. J Steroid Biochem 1988; 31: 161–6
   PubMedGoogle Scholar
• Baulieu E E. RU 486: An antiprogestin steroid with contragestive activity in women. The antiprogestin steroid RU 486 and human fertility control, E E Baulieu, S Segal. Plenum Press, New York 1985; 1–25
   Google Scholar
• Kovacs L, Sas M, Resch B, et al. Termination of very early pregnancy by RU 486—an antiprogestational compound. Contraception 1984; 29: 399–410
   PubMed Web of Science ®Google Scholar
• Haspels A. Interruption of early pregnancy by an anti‐progestional compound, RU 486. Eur J Obstet Gynec Reprod Biol 1985; 20: 169–75
   PubMed Web of Science ®Google Scholar
• Cameron I, Michie A, Baird D. Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (Gemeprost). Contraception 1986; 34: 459–68
   PubMed Web of Science ®Google Scholar
• Couzinet B, Le Strat N, Ulmann A, Baulieu E E, Schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). N Engl J Med 1986; 315: 1565–9
   PubMed Web of Science ®Google Scholar
• Elia D. Uses of RU 486: A clinical update. IPPF Medical Bulletin 1986; 20: 1–2
   PubMedGoogle Scholar
• Shoupe D, Mishell D, Jr, Brenner P, Spitz I. Pregnancy termination with a high and medium dosage regimen of RU 486. Contraception 1986; 33: 455–61
   PubMed Web of Science ®Google Scholar
• Mishell D, Jr, Shoupe O, Brenner B, et al. Termination of early gestation with the anti‐progestin steroid RU 486: medium versus low dose. Contraception 1987; 35: 307–21
   PubMed Web of Science ®Google Scholar
• Birgerson L, Odlind V. The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception 1988; 38: 391–400
   PubMed Web of Science ®Google Scholar
• Grimes D, Mishell D, Jr, Shoupe D, Lacarra M. Early abortion with a single dose of the antiprogestin RU‐486. Am J Obstet Gynecol 1988; 158: 1307–12
   PubMed Web of Science ®Google Scholar
• Ylikorkala O, Alfthan H, Kääriäinen M, Rapeli T, Lähteenmäki P. Outpatient therapeutic abortion with mifepristone. Obstet Gynecol 1989; 74: 653–7
   PubMed Web of Science ®Google Scholar
• Birgerson L, Odlind V. Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane. Fertil Steril 1987; 48: 565–70
   PubMed Web of Science ®Google Scholar
• Verves H, Haspels A. Preliminary results with the antiprogestational compound RU‐486 (mifepristone) for interruption of early pregnancy. Fertil Steril 1985; 44: 627–32
   PubMed Web of Science ®Google Scholar
• Swahn M, Cekan S, Wang G, Lundström V, Bygdeman M. Pharmacokinetic and clinical studies of RU 486 for fertility regulation. The antiprogestin steroid RU 486 and human fertility control, E E Baulieu, S Segal. Plenum Press, New York 1985; 249–58
   Google Scholar
• Rodger M, Baird D. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 1987; ii: 1415–8
   Google Scholar
• Ji G, Gen‐Mei Q, Yu‐Ming W, et al. Pregnancy interruption with RU 486 in combination with dl‐15‐methyl‐prostaglandin‐F2α‐methyl ester the Chinese experience. Contraception 1988; 38: 675–83
   PubMed Web of Science ®Google Scholar
• Rodger M, Logan A, Baird D. Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (Gemeprost). Contraception 1989; 39: 497–502
   PubMed Web of Science ®Google Scholar
• Cameron I, Baird D. Early pregnancy termination: a comparison between vacuum aspiration and medical abortion using prostaglandin (16,16 dimethyl‐trans Δ2‐PGE, methyl ester) or the antiprogestogen RU 486. Br J Obstet Gynecol 1988; 95: 271–6
   PubMedGoogle Scholar
• Urquhart D, Templeton A. Mifepristone (RU 486) and second‐trimester termination. [Letter]. Lancet 1987; ii: 1405
   Google Scholar
• Croxatto H, Salvatierra A, Romero C, Spitz I. Late luteal phase administration of RU 486 for three successive cycles does not disrupt bleeding patterns or ovulation. J Clin Endocrinol 1987; 65: 1272–7
   Web of Science ®Google Scholar
• Van Santen M, Haspels A. Interception III: Postcoital luteal contragestion by an antiprogestin (mifepristone, RU 486) in 62 women. Contraception 1987; 35: 423–31
   PubMed Web of Science ®Google Scholar
• Lähteenmäki P, Rapeli T, Kääriäinen M, Alfthan H, Ylikorkala O. Late postcoital treatment against pregnancy with antiprogesterone RU 486. Fertil Steril 1988; 50: 36–8
   PubMed Web of Science ®Google Scholar
• Van Santen M, Haspels A. Interception IV: Failure of mifepristone (RU 486) as a monthly contragestive, “Lunarette”. Contraception 1987; 35: 433–8
   PubMed Web of Science ®Google Scholar
• Cabrol D, Bouvler D'Yvoire M, Mermet E, Cedard L, Sureau C, Baulieu E E. Induction of labor with Mifepristone after intrauterine fetal death. [Letter]. Lancet 1985; ii: 109
   Google Scholar
• Paris F, Henry‐Suchet J, Tesquier L, et al. Intéret d'un stéroide à action antiprogestérone dans le traitement de la grossesse extra‐utérine. Rev Fr Gynecol Obstet 1986; 81: 33–5
   PubMedGoogle Scholar
• Kenigsberg D, Porte J, Hull M, Spitz I. Medical treatment of residual ectopic pregnancy: RU 486 and methotrexate. Fertil Steril 1987; 47: 702–3
   PubMed Web of Science ®Google Scholar
• Nleman L, Merriam G, Lorlaux L, Wehmann R. Follicular phase administration of the progesterone antagonist RU 486 delays ovulation. [Abstract]. 68th Meeting of the Endocrine Society. Endocrine Society, Anaheim 1986, no 158
   Google Scholar
• Cheang A, Ho K, Sen D, Ratnam S. A placebo presented at the controlled, dose finding study of the antiprogestin RU 486 (mifepristone) for preoperative cervical dilatation. International Conference of Reproductive Endocrinology, Beijing, November, 2–61988, Abstract No. 34
   Google Scholar
• Rádestad A, Christensen N, Strömberg L. Induced cervical ripening with mifepristone in first trimester abortion. Contraception 1988; 38: 301–12
   PubMed Web of Science ®Google Scholar
• Romieu G, Maudelonde T, Ulmann A, et al. The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trial. Bull Cancer (Paris) 1987; 74: 455–61
   PubMed Web of Science ®Google Scholar
• Gaillard R, Poffet D, Rlondel A, Saurat J ‐H. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol 1985; 61: 1009–11
   PubMed Web of Science ®Google Scholar
• Nleman L, Chrousos G, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61: 536–40
   PubMed Web of Science ®Google Scholar
• Deraedt R, Bonnat C, Busigny M, . Pharmacokinetics of RU 486. The antiprogestin steroid RU 486 and human fertility control, E E Baulieu, S Segal, et al. Plenum Press, New York 1985; 103–22
   Google Scholar
• Heiklnheimo O, Tevliin M, Shoupe O, Croxatto H, Lähteenmäkl P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contraception 1986; 34: 613–24
   PubMed Web of Science ®Google Scholar
• Swahn M, Wang G, Aedo A, Cekan S, Bygdeman M. Plasma levels of antiprogestin RU 486 following oral administration to non‐pregnant and early pregnant women. Contraception 1986; 34: 469–81
   PubMed Web of Science ®Google Scholar
• Kawal S, Nleman L, Brandon D, Udelsman R, Lorlaux L, Chrousos G. Pharmacokinetic properties of the antiglucocorticoid and antiprogestérone steroid RU 486 in man. J Pharmacol Exp Ther 1987; 241: 401–6
   PubMed Web of Science ®Google Scholar
• Salmon J, Mouren M. Radioimmunoassay of RU 486. The antiprogestin steroid RU 486 and human fertility control, E E Baulieu, E Segals. Plenum Press, New York 1985; 99–101
   Google Scholar
• Heiklnheimo O, Lähteenmäkl P LA, Kolvunen E, et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod 1987; 2: 379–85
   PubMed Web of Science ®Google Scholar
• Lähteenmäkl P, Heiklnheimo O, Croxatto H, et al. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 1987; 27: 859–63
   PubMedGoogle Scholar
• Phillbert D, Mogullewsky M, Bonnat C, Busigny M, Pettier J. Influence of human alpha 1‐acid glycoprotein (AAG) on pharmacokinetics and biological activity of RU 486. Presented at the 68th Meeting of the Endocrine Society, Anaheim, June, 25–271986, Abstract No. 1006
   Google Scholar
• Heiklnheimo O, Haukkamaa M, Lähteenmäkl P. Tissue concentrations of RU 486 in women following oral intake. J Clin Endocrinol Metab 1989; 68: 270–5
   PubMedGoogle Scholar
• Heikinheimo O. Pharmacokinetics of the antiprogestérone RU 486 in women during multiple dose administration. J Steroid Biochem 1989; 32: 21–5
   PubMedGoogle Scholar
• Heiklnheimo O, Croxatto H, Salvatierra A, Chang C, Luuk kalnen T, Lähteenmäkl P. Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans. Hum Reprod 1987; 2: 645–8
   PubMed Web of Science ®Google Scholar
• Burger W, Marshall R. Battle of the abortion pill. Newsweek Nov 7, 1988; 8–9
   Google Scholar
• Coles P. French drug under attack. Nature 1989; 338: 367
   PubMed Web of Science ®Google Scholar